FullHope Biomedical CoROCO:7773 14 Current Ratio is 19.93 as of Dec. 2025, which is at its 10-year median of 19.93. GuruFocus rates ROCO:7773 with a GF Score™ of 14/100. The stock has 1 warning sign investors should review. Among 1,411 Biotechnology companies, FullHope Biomedical Co ranks better than 92.35% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. FullHope Biomedical Co's current ratio for the quarter that ended in Dec. 2025 was 19.93.
FullHope Biomedical Co has a current ratio of 19.93. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for FullHope Biomedical Co's Current Ratio or its related term are showing as below:
ROCO:7773'
s Current Ratio Range Over the Past 10 Years
Min: 4.6 Med: 19.93 Max: 38.42
Current: 19.93
During the past 5 years, FullHope Biomedical Co's highest Current Ratio was 38.42. The lowest was 4.60. And the median was 19.93.
ROCO:7773's Current Ratio is ranked better than 92.35% of 1411
companies
in the Biotechnology industry
Industry Median: 3.88
vs ROCO:7773: 19.93
FullHope Biomedical Co (ROCO:7773) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
FullHope Biomedical Co Current Ratio Related Terms
FullHope Biomedical Co Current Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:7773 vs VRTX, REGN, ALNY: Current Ratio Comparison
For the Biotechnology subindustry, FullHope Biomedical Co's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
FullHope Biomedical Co Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, FullHope Biomedical Co's Current Ratio distribution charts can be found below:
* The bar in red indicates where FullHope Biomedical Co's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FullHope Biomedical Co (ROCO:7773) has a Current Ratio of 19.93 as of Dec. 2025. This is near median its historical median of 19.93. Over the past decade, FullHope Biomedical Co's Current Ratio has ranged from 4.60 to 38.42. According to the industry distribution chart, FullHope Biomedical Co ranks #108 out of 1411 companies in the Biotechnology industry, placing it in the top 7.7%.
Is FullHope Biomedical Co's Current Ratio too high?
FullHope Biomedical Co's current Current Ratio of 19.93 is near median its 10-year median of 19.93. Over the past 10 years, this metric has ranged from a low of 4.60 to a high of 38.42. The Biotechnology industry median Current Ratio is 3.88. FullHope Biomedical Co's value of 19.93 is 413.7% above this industry median. Based on the distribution chart, FullHope Biomedical Co ranks #108 out of 1411 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, FullHope Biomedical Co has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does FullHope Biomedical Co's Current Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, FullHope Biomedical Co ranks #108 out of 1411 companies for Current Ratio. This places FullHope Biomedical Co in the top 8% of its industry — outperforming the majority of peers. The industry median Current Ratio is 3.88. FullHope Biomedical Co's value of 19.93 is 413.7% above this benchmark. Historically, FullHope Biomedical Co's own Current Ratio has ranged from 4.60 to 38.42 over the past decade. While the company's 10-year median is 19.93 vs. the industry median of 3.88, FullHope Biomedical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.88, based on 1,411 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. FullHope Biomedical Co's current Current Ratio of 19.93 is 413.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.88 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. FullHope Biomedical Co's current Current Ratio is 19.93, which is near median its own 10-year median of 19.93. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is FullHope Biomedical Co stock overvalued right now?
FullHope Biomedical Co (ROCO:7773) has a current Current Ratio of 19.93. The current Current Ratio is 19.93, which is near median its 10-year median of 19.93 and 413.7% above the Biotechnology industry median of 3.88. FullHope Biomedical Co's overall GF Score™ is 14/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For FullHope Biomedical Co (ROCO:7773), the current Current Ratio is 19.93 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
FullHope Biomedical Co Ltd focuses on immune system-related services and innovative R&D. It establishes cell-based immunotherapies for cancers and autoimmune disorders. Its services are, Immunoprofiling, Circulating Tumor Cells Testing, Regulation of Cell Therapy, Contracting Immune Cell Manufacturing, Immune Cell Bank, Contract Research Organization, and Endotoxin and Mycoplasma Detection Service.
14GF Score
Get the complete analysis for ROCO:7773
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:7773 has been successfully added to your 